Clinical Summary: Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder
Some patients with schizophrenia or schizoaffective disorder remain symptomatic on the highest approved monthly paliperidone palmitate dose, while others want longer intervals between injections without losing maintenance exposure. This analysis addresses both problems by modeling whether LY03010 351 mg can approximate either intensified monthly treatment or less frequent maintenance schedules.
Key Findings
- LY03010 351 mg Q4W deltoid maintenance injections produced higher steady-state exposure than IS 234 mg Q4W, with median [90% PI] Cavg,ss of 76.3 [42, 133] ng/mL versus 50.9 [25.8, 95.4] ng/mL, approximately 50% higher.
- LY03010 351 mg Q4W deltoid maintenance injections were pharmacokinetically comparable to IS 234 mg Q3W, with median [90% PI] Cavg,ss of 76.3 [42, 133] ng/mL versus 67.3 [33.9, 124] ng/mL.
- The proportion of subjects with simulated Cmax,ss exceeding 120 ng/mL was approximately 18.5% with LY03010 351 mg Q4W deltoid and 16.2% with LY03010 351 mg Q4W gluteal versus 12.6% with IS 234 mg Q3W deltoid.
- LY03010 351 mg IDR + Q6W deltoid maintenance dosing closely matched IS 234 mg Q4W deltoid at steady state: Cmax,ss 67.9 [41.3, 108] versus 66.3 [37.3, 113] ng/mL, Ctrough,ss 34.5 [11.9, 74.2] versus 39 [13.7, 84.7] ng/mL, and Cavg,ss 51.7 [28.8, 89.5] versus 50.9 [25.8, 95.4] ng/mL.
- With LY03010 351 mg IDR + Q8W deltoid maintenance dosing, median [90% PI] Cmax,ss and Cavg,ss were 57.8 [35.6, 91.6] and 39.3 [21.7, 67] ng/mL, between IS 234 mg Q4W and 156 mg Q4W, while Ctrough,ss was 20.6 [5.25, 49.9] ng/mL, comparable to IS 117 mg Q4W at 19.6 [6.85, 42.5] ng/mL.
For patients needing more paliperidone exposure than standard PP1M 234 mg Q4W provides, LY03010 351 mg Q4W approximates IS 234 mg Q3W; for patients prioritizing fewer injections, LY03010 351 mg Q6W preserves exposure close to IS 234 mg Q4W. These are pharmacokinetic simulations, not controlled clinical efficacy data, so any off-label use warrants caution and monitoring.
Practice Implications
- Consider LY03010 351 mg Q4W when a patient has an inadequate response to standard 234 mg Q4W and a higher-exposure strategy is being weighed, because simulated exposure was similar to IS 234 mg Q3W.
- If extending the interval is the goal without materially changing monthly 234 mg exposure, LY03010 351 mg Q6W is the closest simulated match to IS 234 mg Q4W.
- Monitor closely for adverse effects when using intensified exposure regimens, particularly extrapyramidal symptoms and prolactin levels, because approximately 18.5% of subjects on LY03010 351 mg Q4W deltoid had simulated Cmax,ss exceeding 120 ng/mL.
- Do not expect major exposure differences between deltoid and gluteal maintenance injections for LY03010 351 mg, as simulations showed similar steady-state paliperidone exposure across injection sites.
